

REMARKS

Claims 13-15, 31 and 32 were previously pending in this application. Claim 31 has been amended. New claim 62 has been added. As a result claims 13-15, 31-32 and 62 are pending for examination with claims 13 and 31 being independent claims. No new matter has been added.

Applicants would like to thank the Examiners for the courtesy extended in granting the telephonic interview of March 5, 2004. In the Interview Summary mailed March 8, 2004, the Examiner indicated that written description and enablement rejections were discussed. Applicant believes this is an incorrect statement of the issues discussed. Applicant agrees that the written description rejection was discussed, along with the indefiniteness rejection (35 U.S.C. §112, second paragraph). However, as there is no outstanding enablement rejection of the claims, no such rejection was discussed.

Objection to the Specification

The Examiner objected to the disclosure based on the priority information. As suggested by the Examiner, Applicant has amended the relevant paragraphs to include patent numbers. Reconsideration is respectfully requested.

Objections to the Claims

The Examiner objected to claim 31 based on several informalities. Applicant has amended the claim to limit it to the elected invention (use of antibodies in the claimed method) and to correct the text of the claim as suggested by the Examiner. Reconsideration is respectfully requested.

Rejections Under 35 U.S.C. §112, First Paragraph

The Examiner has rejected claims 13-15, 31 and 32 under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Applicant respectfully traverses the rejection.

Examiner Blanchard and Examiner Helms conducted a telephone interview on March 5, 2004 with Applicant's representatives John Van Amsterdam and Marie Jepson, and Assignee's representative Dr. Jonathan Skipper to address the issues underlying the rejection of claims 13-15, 31, and 32 under 35 U.S.C. §112. Applicants provide the following summary of the content of the telephone interview.

The interview began with a summary of the claimed invention and the related field of gastric cancer diagnostics by Dr. Jonathan Skipper. Methods set forth in the application were summarized by Dr. Skipper in the telephone interview. Dr. Skipper described the process by which the proteins that give rise to the immune response in gastric cancer were identified by Applicant using SEREX methodology. Dr. Skipper indicated that the polypeptides that Applicant identified as giving rise to an immune response in gastric cancer can be used to diagnose gastric cancer in patients. Dr. Skipper explained that the claimed methods of diagnosing gastric cancer include contacting sera obtained from a subject with sterol carrier protein-X/sterol carrier protein-2 polypeptides identified by Applicants as expressed in patients with gastric cancer. After contacting the polypeptides with the sera, one can determine whether antibodies are present in the subject's sera that recognize the polypeptide, i.e., whether the subject has mounted an immune response against the polypeptide. The presence of such antibodies in the sera is an indication of gastric cancer in that subject, either a primary tumor or a metastatic tumor that expresses the polypeptide.

Examiner Helms requested Applicants explain how the techniques used to screen patients known to have gastric cancer, as shown in the previously submitted Declaration, could be used to diagnose patients where it is not known that the patients have gastric cancer. Dr. Skipper responded stating that the patients in the study submitted in the Declaration (dated June 24, 2003, submitted July 11, 2003) were not selected, and that these results provided a demonstration of the diagnostic value of Applicant's claimed method. Applicant's representative John Van Amsterdam added that the submitted Declaration showed that normal non-cancerous patients had no sterol carrier protein-X/sterol carrier protein-2 antibodies and the technique would therefore only identify those patients with gastric cancer.

Examiner Helms requested additional information regarding the open reading frames of the identified nucleic acid sequences, SEQ ID NOs:19-22. The open reading frames for these nucleic acids are provided with this amendment (see Exhibits A-1, A-2, A-3 and A-4, translated sequences). Applicant's representative John Van Amsterdam stated that the sequences found using the SEREX method had to have open reading frames which were the same as the SCP-X protein in gastric cancer in order to be identified using this method. Dr. Skipper added that once the nucleic acid sequences are discovered they are run through a database for matches and that the identified sequences matched nucleic acid molecules encoding the sterol carrier protein-X.

Examiner Helms also requested the open reading frames because according to the Examiner, there was nothing in the claims stating the function of the SCP-X protein or how to identify which region the nucleic acid sequence matched. Dr. Skipper responded stating that it is only required that the nucleic acid encode an immunogenic protein and from knowing the nucleic acid sequence it would be routine for one of ordinary skill in the art to determine the corresponding region of SCP-X.

Examiner Blanchard asked how one would differentiate from other antibodies present in the mix. Dr. Skipper responded by providing some of the method details for a Western blot or ELISA assay for detecting an antibody of interest and stated that these were standard methods well known in the art that would distinguish between a variety of antibodies by reducing non-specific binding of antibodies.

Based on the specification as filed and on the information and arguments presented in the telephonic interview of March 5, 2004, which are summarized above, Applicant respectfully requests that the Examiner reconsider and withdraw the rejection of claims 13-15, 31, and 32 under 35 U.S.C. § 112, first paragraph.

Rejections Under 35 U.S.C. §112, Second Paragraph

The Examiner has rejected claims 31 and 32 under 35 U.S.C. §112, second paragraph, as indefinite. Applicant has amended the claims to address the first two rejections, and respectfully traverses the third rejection.

The Examiner stated three indefiniteness rejections, as follows.

(1) Claims 31 and 32 were rejected for the recitation of “parameter” in claim 31. Applicant has amended claim 31 to specify that antibodies are assayed in the claimed method. Accordingly, Applicant believes the rejection is moot.

(2) Claims 31 and 32 were rejected for the recitation in claim 31 of “said peptide of said protein,” for which there was alleged not to be antecedent basis. Applicant has amended claim 31 to remove recitations of peptides in the claimed method. Accordingly, Applicant believes this rejection is moot also.

(3) Claims 31 and 32 were rejected for the recitation of “following progress of a therapeutic regimen” in claim 31. Applicant respectfully requests reconsideration of the rejection based on the information provided in the telephonic interview.

As established, the presence of antibodies to SCP-X/SCP-2 are an indicator of gastric cancer in a patient. Patients have gastric cancer may be treated by surgery to remove the cancer, and/or radiation therapy or chemotherapy to kill the tumor, thereby removing the source of the SCP-X/SCP-2 protein. The reemergence at a later time of antibodies to SCP-X/SCP-2 would be an indication of regrowth of the tumor or of a metastatic tumor expressing SCP-X/SCP-2. Therefore, Applicant asserts that the progress of a therapeutic regime can be followed using the claimed method in which the presence or level of antibodies is determined at separate times.

In view of the foregoing claim amendments and arguments, Applicant respectfully requests reconsideration and withdrawal of the rejection of claims 31 and 32 under 35 U.S.C. §112, second paragraph.

CONCLUSION

In view of the foregoing amendments and remarks, this application should now be in condition for allowance. A notice to this effect is respectfully requested. If the Examiner believes, after this amendment, that the application is not in condition for allowance, the Examiner is requested to call the Applicant's attorney at the telephone number listed below.

If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicant hereby requests any necessary extension of time. If there is a fee occasioned by this response, including an extension fee, that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Respectfully submitted,
Yuichi Obata, Applicant

By: 
John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
Telephone: (617) 720-3500

Docket No. L0461.70112US00
Date: March 11, 2004
x03/11/04x

[ExPASy Home page](#)[Site Map](#)[Search ExPASy](#)[Contact us](#)[Proteomics tools](#)Search for

Exhibit A-1 (SEQ ID NO: 19)

Translate Tool - Results of translation

Please select one of the following frames:

5'3' Frame 1

RQKKLF Stop FSIKHSSQSIILSYISLNFKKK Stop H Stop Y Stop KN Stop EKR
 Stop Met QIIKLT Stop KRKIITKD Stop ERYKLLK Stop DYNLKTASESKLYCSI
 XLNDGVL Stop LIH Stop FFKKETHVKNIFILKISLCSSSDHISFILIWEXN
 TVSDS Met KCKIFRFLISLILXTIEKLIND Met KCTTLITGQLLALCFLLS
 SPKGKLLN Stop IFSRIILKYTL Stop AKQKLFCLHSSLGFYCS Stop FYSET
 QFYPRP Stop LPY Stop LCXAQLFANS

5'3' Frame 2

ARKSYFNFLNILLKALFYPISSH Stop ILRNNISIRKTRKKDKCR Stop LN
 LHEKGKL Stop QRTENVIN Stop NEIII Stop KLHLKANFIVQLXL Met Met VF
 YD Stop YTDFSRRKP Met LKIFLF Stop K Stop ACVQALIIFLLF Stop FGXKIL
 FLIA Stop NAKFLDF Stop SH Stop F Stop XLLRN Stop L Met T Stop SAQH Stop LLA
 SCWHCVSYLVLPRENS Stop IESSAE Stop SLNILCKQNKSFVYIVLWD
 FTVPNFILKLNFTPDHNYHINFVXHSCLP

5'3' Frame 3

PEKVILIFY Stop TFFSKHYFILYLTEF Stop EITLVLEKLGKKINADN Stop
 TY Met KKENYNKGLRTL Stop IE Met RL Stop FENCIS Stop KQTLLFNXYX Stop
 Stop WCF Met TNTLIFQEGNPC Stop KYFYFKNKP VF KL Stop SYFFYFDLG
 XKYCF Stop Stop HE Met QNF Stop IFNLTNFXNY Stop EID Stop Stop HEVHNTN
 YWPAVGIVFLT Stop FSQGKTLKLN LQQNNP Stop IYFVSKTKAFLFT
 Stop FFGILLFLILF Stop NSILPQTIITILTLXCTVVCQF

3'5' Frame 1

Stop IGKQLCXTKLIW Stop LWSGVKLSFRIKLGTVKSQRT Met Stop TKKL
 LFCLQSIFKDYSIEDSI Stop EFSLGRTK Stop ETQCQQLASN Stop CCALH
 VINQFLNSX Stop N Stop Stop D Stop KSKNFAFHAIRNSIXFPNQNKRN Met I
 RA Stop TQAYF Stop NKNIFN Met GFLLEKSVY Stop S Stop NTIIKXN Stop TIK
 FAFRCSFQIIISFQFITFSVLCYNFPFSCKFNYLHLSFFLVFLIL Met LF
 LKIQ Stop DIG Stop NNALRR Met FNRKLLK Stop LFLA

3'5' Frame 2

ELANNCAXQS Stop YGNYGLG Stop N Stop VSE Stop N Stop EQ Stop NPKELC
 QKSFCFAYKVYLRIILLKIQFKSFPLGELSKKHANANSWPVISVVHF
 Met SLINFSIVXKISEIKNLKILHF Met LSETVFXSQIKIKEI Stop SELEHR
 LIFKIKIFLTWVSFLKNQCISHKTPSLXIIEQ Stop SLLSDAVFKL Stop SH
 FNL Stop RSQS FVIIFLHVSLIICIYLF S Stop FF Stop Y Stop CYFLKFSEI
 Stop DK I Met L Stop EECLIEN Stop NNFFW

3'5' Frame 3

NWQTTVXNKVN**Met** VIM**Met** VWGKIEFQNKIRNSKIPKNYVNKKAFVL
LTKYI**Stop** GLFC**Stop** RFNLRVFPWEN**Stop** VRNT**Met** PTAGQ**Stop** LVLCTS
CH**Stop** SISQ**Stop** XLKLVRLLKI**Stop** KFCISCYQKQYFXPKSK**Stop** KKYDQ
SLNTGLFLK**Stop** KYF**Stop** HGFPS**Stop** KISVLVIKHHH**Stop** X**Stop** LNNKV
CFQ**Met** QFSNYNLISINYVLSPLL**Stop** FSFF**Met** **Stop** V**Stop** LSAFIFFPSS
NTNVIS**Stop** NSVRYRIK**Stop** CFEKNV**Stop** **Stop** KIKITFSG

[ExPASy Home page](#)[Site Map](#)[Search ExPASy](#)[Contact us](#)[Proteomics tools](#)

[ExPASy Home page](#)[Site Map](#)[Search ExPASy](#)[Contact us](#)[Proteomics tools](#)Search for

Exhibit A-2 (SEQ ID NO: 20)

Translate Tool - Results of translation

Please select one of the following frames:

5'3' Frame 1

ILIFY **Stop** TFFSKHYFILYLTEF **Stop** XITLVLEKLGKKXNADN **Stop** TY
Met KKENYNKGLRTL **Stop** IE Met RL **Stop** FENCIS **Stop** KQTLLFNYS **Stop** **Stop**
WCF Met TNTLIFQ **Stop** GNPC **Stop** KYFYFKNKPVFKL **Stop** SYFFYFDLGR
KYCF **Stop** **Stop** HE Met QNF **Stop** IFNLXNFKNY **Stop** EID **Stop** **Stop** HEVHNTN
YWPAGIVFLT **Stop** FSQGKLLN **Stop** IFSXITLNLIC **Stop** PNKTFLFT **Stop**
FFGFYCS **Stop** FYSETPFFPRP **Stop** LPYLTLLCTVV

5'3' Frame 2

F **Stop** FSIKHSSQSIILSYISLNFXXK **Stop** H **Stop** Y **Stop** KN **Stop** EKRX Met QIIK
LT **Stop** KRKIITKD **Stop** ERYKLK **Stop** DYNLKTASESKLYCSIILNDGVL
Stop LIH **Stop** FFNKETHVKNIFILKISLCSSSDHISFILIWEENTVSDS Met
KCKIFRFLIXLILRTIEKLIND Met KCTTLITGQLLALCFLSSPKENS
Stop TESSXE **Stop** P **Stop** IYFVSQTKLFC LHSSLDFTVPNFILKLHFSPDHN
YPI **Stop** LCYAQL

5'3' Frame 3

FNFLNILLKALFYPISSH **Stop** ILXNNISIRKTRKKDXCR **Stop** LNLHEKG
KL **Stop** QRTENVIN **Stop** NEIII **Stop** KLHLKANFIVQLFL Met Met VFYD **Stop**
YTDFSIRKP Met LKIFLF **Stop** K **Stop** ACVQALIIFLLF **Stop** FGKKILFLIA
Stop NAKFLDF **Stop** SX **Stop** F **Stop** ELLRN **Stop** L Met T **Stop** SAQH **Stop** LLASCW
HCVSYLVLPKTLKLNQXNNLKYTLLAKQNFFVYIVLWILLFLILF
Stop NSIFPQTIITLNFV Met HSC

3'5' Frame 1

NNCA **Stop** QS **Stop** IG **Stop** LWSGEKWSFRIKLGTVKSKELCKQKSFVWLT
KYI **Stop** GYXAEDSV **Stop** EFSLGELSKKHNSWPVISVVHF Met SLINF
SIVLKIXEIKNLKILHF Met LSETVFSSQIKIKEI **Stop** SELEHRLIFKIKIF
LTWVSLLNQCISHKTPSLRIEQ **Stop** SLLSDAVFKL **Stop** SHFNL **Stop** R
SQSFVIIFLFHVSLIICIXLFS **Stop** FF **Stop** Y **Stop** CYXLKFSEI **Stop** DKIMet L
Stop EECLIEN **Stop** N

3'5' Frame 2

TTVHNKVK **Stop** GNYGLGKNGVSE **Stop** N **Stop** EQ **Stop** NPKNYVNKKVLF
G **Stop** QSIFKVIXLKIQFKSFPWEN **Stop** VRNT Met PTAGQ **Stop** LVLCTSC
H **Stop** SISQ **Stop** FLKLXRLKI **Stop** KFCISCYQKQYFLPKSK **Stop** KKYDQS
LNTGLFLK **Stop** KYF **Stop** HGFPY **Stop** KISVLVIKHHH **Stop** E **Stop** LNNKVC
FQ Met QFSNYNLISIYNVLSPLL **Stop** FSFF Met **Stop** V **Stop** LSAXIFFPSFSN
TNVIX **Stop** NSVRYRIK **Stop** CFEKNV **Stop** **Stop** KIK

3'5' Frame 3

QLCITKLN RVIMet VWGKMet EFQNKIRNSKIQRTMet Stop TKKFCLANK
VYLRLFXStop RFSLRVFLGRTKStop ETQCQQLASNStop CCALHVINQF
LNSSStop NStop XDStop KSKNF AFHAIRNSIFFPNQNKRNMet IRAStop TQ
AYFStop NKNIFNMet GFLIEKSVYStop SStop NTIIKNNStop TIKFAFRCSF
QIIISFQFITFSVLCYNFPFSCKFN YLHXSFFLVFLILMet LFXKIQStop D
IGStop NNALRRMet FNRKLLK

[ExPASy Home page](#)[Site Map](#)[Search ExPASy](#)[Contact us](#)[Proteomics tools](#)

[ExPASy Home page](#)[Site Map](#)[Search ExPASy](#)[Contact us](#)[Proteomics tools](#)Search for

Exhibit A-3 (SEQ ID NO: 21)

Translate Tool - Results of translation

Please select one of the following frames:

5'3' Frame 1

LTQLLLRCLG**Met**LEKNIWKN**Met**EQKLNTLQKLDGKIINIQLITRIPS
SK**Met**NTV**Stop****Met**K**Stop**WHLKKFLIF**Stop**LSYNVVPLQ**Met**VLQQQFWP
VKHLYRS**Met**ACNPKLWKFWHKK**Stop****Stop**LICQARLKKKALLKWLAL
I**Stop**VKKLQENAB**Met**RNL**Stop**HQ**Met**ILT**Stop****Stop**NFTIAFLPTNSLL**Met**
KHWDVSVQKDKVQRWLIIEIIH**Met**EESGS**Stop**ILVVD**Stop**FORDTH**Stop**
ALQVLLSVQNSAGS**Stop**EGKPEKRQSSWCKGGSXA**Stop**FXHWRNCG
CNTLQDGVFPEAASSF**Stop**NSSKLKXVPTKLCKXXV**Stop**XKIXF**Stop**R
XIEKEXXKREXGTICERKXXREFLPFKGKXWPWGVKXGHPGVVG

5'3' Frame 2

SPSCSSDVWVCWKRTYGKIWNKN**Stop**TLCKNW**Met**EKS**Stop**TFS**Stop**
StopPVFPVPR**Stop**IQFR**Stop**SDGI**Stop**RSF**Stop**FFDYLT**Met**LSHFRWCCS
SNFGQ**Stop**SICTEVWPAIQSCGNFGTRNDD**Stop**FAKL**Stop**RKKHY
StopNGWL**Stop**YE**Stop**RSCKK**Met**L**Stop**EIWPDTK**Stop**Y**Stop**RNRTSRLLF
YQRTPYL**Stop**STGTLRRTRCNAG**Stop****Stop**RR**Stop**YIWRKVGHKS**Stop**
WWTDFKGTPTRRYRSCSVCRTLLAERGSRKRGKVPGAVALXHN
LXIGGTVVVTLTK**Met**GFSRKPPVPFRTHQN**Stop**SXFQPSSASXXFXX
KSXFKXGLRRKXXRGXGEQFVKEKXXGNFCPSRGXNGPGG**Stop**KXA
TLGWWD

5'3' Frame 3

HPVAPQ**Met**FGYAGKEH**Met**EKYGTKIEHFAKIGWKNHKHSVNNPYS
QFQDEYSLDEV**Met**ASKEVFDLTLQCCPTSDGAAAILASEAFVQK
YGLQSKAVEILAQ**Met****Met**TDLPSSFEEKSIIK**Met**VGFD**Met**SKEAAR
KCYEKSGLTPNDIDVIELHDCFSTNELLYEALGLCPEGQGATLVDR
GDNTYGGKWVINPSGGLISKGHPLGATGLAQCAELCWQLRGEAGK
EAKFLVQRWLCXIIXALEELWL**Stop**HSTRWGFPGSRQFLLELIKIEA
XSNQALQXXGLXXNXVLKXD**Stop**EGNXKEGXGNL**Stop**KKNXXGIF
ALQGEX**Met**ALGGKRXPPWGGG

3'5' Frame 1

IPPPQGGXLLPPRAIXSP**Stop**RAKIPXXFFFHKLFPXPSXXFPSQSXFK
XRFXXKXXTCRAWLEXASIL**Met**SSKRNWRLPGKPHLVECYNHSSSN
X**Stop**I**Met**XQSHLCTRNFASFPA SPLSCQQSSAH**Stop**ARPVAPSGCPFEI
SPPLGF**Met**THFPYVLSPLSTSVAPCPSGQSPSAS**Stop**VRSSLVEKQS
StopSSITSISFGVRPDFS**Stop**HFLAASLLISKPTIL**Met**LFSSNELGKSVI
ISCAKISTALDCRPYFCTNASLAKIAAAAPSEVGQHCKIVKKSKTSL
DAITSSKLYSSWNWEYGLLTECL**Stop**FFHPIFAKCSIFVPYFSICSFPA
YPNI**Stop**GATG**Stop**

3'5' Frame 2

SHHPRVAXFYPPGPXFPLEGQKFXPXFSTNCSXFPLXXFLLNXPLK
XDFXLNXXLAELGWNXLQF **Stop Stop** VLKGTGGFRENPI **Stop** SVTTTV
PP **Met** XKLCXRATFAPGTLPLFRLPLSAASRVLHTEQDL **Stop** RLVGVP
LKSVHH **Stop** DL **Stop** P TFLH **Met** YYLLYQPALHLVLLDRVPVLHK **Stop** G
VRW **Stop** KSNREVLLRQYHLVSGQISHSIFLQLLYSYQSQPF **Stop Stop** C
FFLQTSLANQSSFLVPKFPQLWIAGHTSVQ **Met** LHWPKLLLQHHLKW
DNIVR **Stop** SKNQKLL **Stop Met** PSLHLNCIHLGTGNTGY **Stop** LNVYDFS
QFLQSVQFLFHIFPYVLFQHTQTSEEQLGE

3'5' Frame 3

PTTPGWXSFTPQGHXFPLKGKNSXXIFLSQIVPXSLFXVSFSIXL **Stop**
NXIXX **Stop** TXXLQSLVGXGFNFDEF **Stop** KELAASGKTPSCRVLQPQFL
QCXNYXAEPLHQELCLFSGFPSQLPAEFCTLSKTCSA **Stop** WVSL **Stop**
NQSTTRIYDPLSSICISSINQRCTLSFWTESQCFISKEFVGRKAIVKF
YYVNIIWCQARFLIAFSCSFFTHIKANHFNNAFFFKRAWQISHHFLC
QNFHSFGLQAILLYKCFTGQNCCCSI **Stop** SGTTL **Stop** DSQKIKNFFR
CHHF **Stop** TVFILELGIRVIN **Stop Met** F **Met** IFPSNFCKVFNFCSIFFH **Met** F
FSSIPKHLRSNWV

[ExPASy Home page](#)[Site Map](#)[Search ExPASy](#)[Contact us](#)[Proteomics tools](#)

[ExPASy Home page](#)[Site Map](#)[Search ExPASy](#)[Contact us](#)[Proteomics tools](#)Search for

Exhibit A-4 (SEQ ID NO: 22)

Translate Tool - Results of translation

Please select one of the following frames:

5'3' Frame 1

GQKXLFFPIXXPXQXIIXPYXXXXXXXXXXYLXX**Stop**KTXEKK**Stop**XQI
XNLX**Stop**KXKFXPDXNXNXNYXKXXETXLXGPIIXXEXXX
XLXPXFSNXEXXXKXXILKITXXPTDXIPXIWIGEKNXVXXTXX
XKXFKFLTPLXLKXXEXXIXDLNCQPXXXATXGXXXPYLXPPRKXL
XXXLXQNNP**Stop**XSLVTKXKPFXXSLGFNGSPIXSXTXFSPXPXL
PFYLGKXQXFAXPQXSXXPXXLSPXPWEKRDXSPP**Stop**KTTFPXLWP
RXXSRLNPNKK

5'3' Frame 2

AKKXYXNFLLLXXLXKXLFXPXXXXXXXXXXTFXXKKPXKKNNXKXL
T
XLEXGNXYQXXEXXXIXXXIIXXXRXXKPPXX**Met**VQLSXXRXXFX
StopXXDFPIXXPXLKXXFF**Stop**K**Stop**PXXQPXIXFLXFGLGKKXXFXI
XXXAXFLNF**Stop**PPXF**Stop**XLXKXXLXT**Stop**IANPXXXPXVGXXFLT
X
SPQGXXLXXXSXKITLXYPW**Stop**PXQNLFXLXXPWDLTGPQFXXEP
XFPXNHXYHFTLVRXSLXXRKXVXFPXXFPXLLGKNGXGPPLKKQ
PSPXFGPXXXPV**Stop**IRTIK

5'3' Frame 3

PKKXIXISY**Stop**XSSXXHYXTLXXXXFXKXPXXLKNXGKKIXANX
StopPXLKXEIXTXGXKXX**Stop**XEXKLXXEXGXNQQXXWSNYPXXGX
XXTNXXIFQXGXXX**Stop**XXFXFKNNXXSNPXSXSFXLDWGKKXXSX
YXEXQXF**Stop**IFNPPXFKXYXKXXDXLELPTLXXGHXWXXXSLLXP
PKEXP**Stop**XEXXP**Stop**PLXILGNQXKTFXVYXXLGI**Stop**RVPNXIXN
P
PXFPTIXTILPW**Stop**GXXVCXXAXQXXSXGXFPRLGKTGXVPPLK
NNLPXPLAQXXFPSKSEQ**Stop**K

3'5' Frame 1

LFIVRI**Stop**TGXXPGPKXGEGCFLRGGXIPFFPRXGGKXXGXXTXLR
XCKXLXLT
TKVKW**Stop**XWXXGKXGXGXNWXGPKSQQGXXKXKRFXX
GYQGXLRVILXEXXXKXFPWGX**Stop**VRXXXPGGXXXGLAIQVXN
XXFXXF**Stop**X**Stop**GG**Stop**KFKXFXXXGXNXIFFPNPNXRNXIXGWX
XGYF**Stop**NXXXFXXFXIGKXGX**Stop**XXXXLXXDNWTXKXGFXXXF
XXIIXXXIXXXVXWXXKXFXSXXVXYLXLFFFXXGFLXXKVXXXXX
XXIGXNNXLXRXNXXRKXX**Stop**XFLA

3'5' Frame 2

FLLFGFRREXXLGQRXGKVVF**Stop**GGDXSRFSQXSGEXAXGXXLXC
XXANXXALPR**Stop**NGXYGXGEXWVXD
XIGDPLNPKXXVNXXKGFXL
VTKDX**Stop**GLFWXXFXLXFLGGXK**Stop**GXXXPXVAXX**Stop**GWQFK
XXIXFXIXFKXRGVKNLKXLXFXVXGXXXFFSPIQXKGX**Stop**XGVGX

XVIFKXKXXLXXXSXLENXXISXXXPXXRIIGPXXLVXXAXFXX **Stop**
FXFXLXXFXSXGXNFXFXQXRLXICXYFFSXVF **Stop** XXRXFXKXXXX
Stop GXIMet XXGGXLIGNXNXFFW

3'5' Frame 3

FYCSDLGXXXWAKXGGRLFFKGGTXPVFPKXRGKXXGEXYXFA
XQXTXPYQGKMet VXMet VXGKXGFXXKLGT **Stop** IPRXX **Stop** XKKVL
XWLPRIXKGYFXGXXX **Stop** XXSLGGXSKEXXAHXWXXXRVGNSSX
Stop XXFX **Stop** XLKXGGLKI **Stop** KXCXXXYEXXFFPQSKXKEXDXGL
XXGLFLKXKXF **Stop** XGXXYWKIXXLXKXPXXG **Stop** LDHXXWFXXP
XXXYNXXNXXFXXLVXISXFKXG **Stop** XFXIIFFXRFFXXKXXXX
XXXXXXRXK **Stop** XFXEXX **Stop** **Stop** EIXIXFFG

[ExPASy Home page](#)[Site Map](#)[Search ExPASy](#)[Contact us](#)[Proteomics tools](#)